Yah I saw the same thing, when Meirav Chovav, called the results of a preliminary PhaseII trial as significant I was jaw dropped. This is part of the long road to FDA approval the long long road, is this the first time she has seen this? What is the percentage of Drugs that get Phase 2 approval but don't make it past 3 and FDA approval? (some confusion there as well it this not the full PhaseII or are the results prelimnary, being literal this is a precurser to the full Phase2 trial. Remember how large the Phase2 was for VPHM it was like 2000 people big)
These are not full results, how can they be significant, this news was speed up to hit now. Perhaps she was given advanced information, but how could that be, if the results are not fully categorized yet. This news was for the conference but hit now, the news basically says that we have a drug, it does not kill patient and while not medically sigificant we can get a measure change which will will lump into the broad category of statistically significant.
BS BS BS
Remember this was just on Influenza A, how can an analyst call preliminary results on a Preminlary Phase 2 test as significant, when a competitors product goes after both A and B types and is fully FDA approved.
This is amazing and yes I think this is one for the SEC to look at. After the trading day I will be sending in all the information I can possible collect. I might not be great with the level 2 side but I have requested the kind assistence of two folks to keep and eagle eye on it. You are welcome to help. Might be wasted breath, but heck why not, my gut tells me that we got MM and analyst hanky panky.
Cheers my friend |
